The Virtuous Fund: A Patient Capital Vehicle for Genuine Biomedical Discovery

An independent analysis of a structural gap in biomedical financing: nine therapeutic targets validated and competed to near-exhaustion within a single inflammatory cascade, while mechanisms of primary resistance remain underfunded. The paper proposes an evergreen, patient-capital fund with a three-tier governance structure (foundation, holding, programmes) allocating capital across four axes: therapeutic rescue, precision medicine, etiological discovery and European manufacturing sovereignty. It describes the investment criteria, liquidity mechanisms for investors, an indicative return profile, and a fixed share of divestiture proceeds directed to an independent research foundation. This is a non-peer-reviewed independent analysis. Keywords: patient capital; evergreen fund; biomedical research financing; drug discovery; pharmaceutical manufacturing; European sovereignty; immune-mediated diseases